Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2017 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook During Presentation at Biotech Showcase 2017

SAN RAMON, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
December 28, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)

SAN RAMON, Calif., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
December 14, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces the Phase 2 Clinical Trial of NeuVax™ (nelipepimut-S) in Ductal Carcinoma in Situ (DCIS) is Open for Enrollment and Screening Patients

SAN RAMON, Calif., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
December 12, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presented Two Posters at the San Antonio Breast Cancer Symposium

NeuVax™ (nelipepimut-S) Phase 2 VADIS trial design in women with ductal carcinoma in situ (DCIS)GALE-301 and GALE-302 Phase 1b clinical data in breast cancer patients SAN RAMON, Calif., Dec. 12,...
November 30, 2016 13:31 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present Two Posters at the San Antonio Breast Cancer Symposium

VADIS: Phase 2 Trial of the Nelipepimut-S Peptide Vaccine in Women with DCIS of the BreastGALE-301 and GALE-302 data in breast cancer patients SAN RAMON, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) --...
November 14, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the Society for Immunotherapy of Cancer Conference 2016

Presentation provides immunologic and booster data on GALE-301/GALE-302 SAN RAMON, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company...
November 09, 2016 16:10 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update

GALE-401 expected to initiate a Phase 3 clinical trial in Q2, 2017Top-Line results from NeuVax™ (nelipepimut-S) PRESENT Clinical TrialWebcast and conference call today at 2:00 p.m. P.T. / 5:00 p.m....
November 03, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer

SAN RAMON, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...
October 31, 2016 16:30 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Reverse Stock Split

1-for-20 Reverse Stock Split Effective November 11, 2016 for Trading November 14, 2016 SAN RAMON, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a...
October 26, 2016 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Report Third Quarter 2016 Financial Results and Provide a Corporate Update on Wednesday, November 9, 2016

SAN RAMON, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right